A Phase I Study of Cancer Peptides Plus GM-CSF and Adjuvant (Montanide ISA 51) Following Completion of Prescribed Chemotherapy or Trastuzumab for TXN2-3M0 or Metastatic Breast Cancer With No Evidence of Disease.
Phase of Trial: Phase I
Latest Information Update: 18 Jun 2013
At a glance
- Drugs Breast cancer vaccine; Granulocyte macrophage colony stimulating factor; Montanide ISA-51
- Indications Advanced breast cancer
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 29 Mar 2011 Actual end date (January 2010) added as reported by ClinicalTrials.gov.
- 29 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.